What Next for Cara Therapeutics Incorporated (NASDAQ:CARA) Stock After Decrease in Shorted Shares?

September 17, 2017 - By Nellie Frank

 What Next for Cara Therapeutics Incorporated (NASDAQ:CARA) Stock After Decrease in Shorted Shares?

Investors sentiment decreased to 1.26 in 2016 Q4. Its down 0.57, from 1.83 in 2016Q3. It turned negative, as 12 investors sold Cara Therapeutics Inc shares while 23 reduced holdings. 18 funds opened positions while 26 raised stakes. 12.12 million shares or 4.42% more from 11.60 million shares in 2016Q3 were reported.
Blackrock Advsr Ltd holds 12,483 shares. Cam Gp A S has invested 0.06% of its portfolio in Cara Therapeutics Inc (NASDAQ:CARA). Franklin has 592,300 shares. New York-based Tower Research Cap Lc (Trc) has invested 0% in Cara Therapeutics Inc (NASDAQ:CARA). Citigroup has invested 0% in Cara Therapeutics Inc (NASDAQ:CARA). Allianz Asset Mngmt Ag reported 260,459 shares. Royal Bancorp Of Canada reported 0% of its portfolio in Cara Therapeutics Inc (NASDAQ:CARA). Manufacturers Life Ins Co The accumulated 15,856 shares. Horrell Capital Management reported 500 shares or 0% of all its holdings. Eam Investors Llc, a California-based fund reported 239,734 shares. Private Advisor Grp Limited accumulated 10,767 shares. Davenport & Co Limited Co has invested 0% in Cara Therapeutics Inc (NASDAQ:CARA). State Street accumulated 348,531 shares or 0% of the stock. Pacad Inv Limited holds 0% or 400 shares. Cubist Systematic Strategies Limited Liability Company owns 1,997 shares or 0% of their US portfolio.

Since March 31, 2017, it had 1 buying transaction, and 0 selling transactions for $9.10 million activity. Shares for $9.10 million were bought by RHO Ventures VI LP on Friday, March 31.

The stock of Cara Therapeutics Incorporated (NASDAQ:CARA) registered a decrease of 2.32% in short interest. CARA’s total short interest was 9.08M shares in September as published by FINRA. Its down 2.32% from 9.30 million shares, reported previously. With 940,700 shares average volume, it will take short sellers 10 days to cover their CARA’s short positions. The short interest to Cara Therapeutics Incorporated’s float is 39.72%.

The stock increased 3.47% or $0.46 on September 15, reaching $13.73. About 1.38 million shares traded or 24.32% up from the average. Cara Therapeutics Inc (NASDAQ:CARA) has risen 206.00% since September 17, 2016 and is uptrending. It has outperformed by 189.30% the S&P500.

Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $447.34 million. The Firm is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It currently has negative earnings. It is developing a class of product candidates that target the body’s peripheral nervous system.

Cara Therapeutics Inc (NASDAQ:CARA) Ratings Coverage

Among 9 analysts covering Cara Therapeutics (NASDAQ:CARA), 8 have Buy rating, 0 Sell and 1 Hold. Therefore 89% are positive. Cara Therapeutics had 20 analyst reports since July 27, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Friday, June 30 by H.C. Wainwright. The stock has “Buy” rating by Laidlaw on Friday, June 30. The firm has “Buy” rating by H.C. Wainwright given on Thursday, October 13. The firm earned “Buy” rating on Thursday, August 3 by Stifel Nicolaus. The rating was maintained by Scotia Capital with “Outperform” on Thursday, November 24. H.C. Wainwright maintained Cara Therapeutics Inc (NASDAQ:CARA) on Friday, August 4 with “Buy” rating. The stock of Cara Therapeutics Inc (NASDAQ:CARA) earned “Buy” rating by Canaccord Genuity on Friday, June 30. The firm has “Buy” rating by Needham given on Wednesday, June 21. Piper Jaffray maintained Cara Therapeutics Inc (NASDAQ:CARA) rating on Friday, August 4. Piper Jaffray has “Buy” rating and $2700 target. The rating was initiated by Cantor Fitzgerald on Wednesday, November 4 with “Buy”.

More important recent Cara Therapeutics Inc (NASDAQ:CARA) news were published by: Fool.com which released: “Here’s Why Cara Therapeutics Rose 9.6% in August” on September 07, 2017, also Nasdaq.com published article titled: “Surging Earnings Estimates Signal Good News for Cara Therapeutics (CARA)”, Fool.com published: “Here’s Why the Best Is Yet to Come for Cara Therapeutics, Inc.” on September 10, 2017. More interesting news about Cara Therapeutics Inc (NASDAQ:CARA) was released by: Fool.com and their article: “Big Investors Are Buying Cara Therapeutics Stock. Should You?” with publication date: August 31, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.